Trade war spoils billionaire Lohia’s chemical acquisitions

Trade war spoils billionaire Lohia’s chemical acquisitions

Aloke Lohia ,Founder and Group CEO of Indorama Ventures Plc. (Bangkok Post file photo)
Aloke Lohia ,Founder and Group CEO of Indorama Ventures Plc. (Bangkok Post file photo)

India-born billionaire Aloke Lohia’s global acquisition spree for chemical plants was designed to give Thailand-based Indorama Ventures Plc more pricing power. But Donald Trump’s trade war has spoiled the party and driven its shares to a record slide.

Indorama’s operating margin has hovered around 4% to 5% the past year, the narrowest since late 2015, as a global economic slowdown sapped demand for its synthetics used in fast fashions and plastic bottles.

The stock -- once a standout with a record share price in 2018 -- has dropped 30% since June 30. It’s on the cusp of an unprecedented fourth-straight quarterly loss, according to data compiled by Bloomberg.

“There is little optimism for any quick recovery as the ongoing trade dispute may continue to hurt profit margins,” said Sutthichai Kumworachai, an analyst at Maybank Kim Eng Securities (Thailand) Plc. “Hope for any rebound would now be in 2020, when most unfavorable factors are expected to subside.”

Mr Lohia has accelerated Indorama’s acquisitions overseas, including investments in the United States, Nigeria and India, as the company aims to spend $5 billion through 2023 to expand production to meet the demand of customers that include Nestle SA, L’Oreal SA and Zara owner Inditex SA.

The shares have lost 47% from a record in May 2018 as the US-China trade dispute and slowing global economic growth eroded demand, while higher material prices raised production costs.

The recent acquisitions will “unleash” growth when the market environment turns favorable again,” Dilip Agarwal, head of Indorama’s feed stock and PET business, told investors at a presentation last month.

The company couldn’t be immediately reached for comment on the share-price slide.

The drop makes the stock attractive as Indorama is among “the most resilient” chemical companies with its diversified businesses and integration, according to DBS Vickers Securities (Thailand) Co.

Indorama’s stock traded at about 8.5 times the company’s 12-month earnings estimate, almost half of the average multiple of 15.3 in the past five years, according to Bloomberg’s data.

Nineteen analysts recommend buying the stock, while three suggest holding it and none advise selling the shares. The average 12-month price target is 47.85 baht, about 45% more than the last close.

Earnings are expected to improve in the six months through December on “volume and margin recovery” bolstered by operations in the US and India, said Duladeth Bik, an analyst at DBS Vickers.

Mr Lohia set up his company in Thailand in 1994. It now operates manufacturing facilities in 101 sites and 31 countries in five continents, according to the company’s website.

Do you like the content of this article?

Activists unfurl Tibet flag at Beijing Olympics flame ceremony

OLYMPIA, Greece: Activists unfurled a Tibetan flag and a banner that said "no genocide" at the flame-lighting ceremony for the 2022 Beijing Winter Olympics in Greece on Monday.


Serious-offence probe into mishandling of 'Boss' case

A seven-member committee has been set up to conduct a serious disciplinary investigation of former deputy attorney general Nate Naksuk's decision to drop a charge of reckless driving causing death against Red Bull scion Vorayuth "Boss" Yoovidhya.


Bye-bye Sinovac

The combination of the Sinovac and AstraZeneca jabs will be replaced by a formula of AZ and Pfizer after the Chinese-made vaccine runs out.